EMNIFY
20.2.2024 15:01:33 CET | Business Wire | Press release
Today, emnify, the leader in cloud-native IoT connectivity solutions, announces the general availability of the industry’s first converged cellular and satellite IoT connectivity on a single emnify IoT eSIM. SuperNetwork SatPlus is offered as part of the emnify SuperNetwork, the leading IoT cellular connectivity service providing multi-network coverage in over 180 countries.
The SuperNetwork SatPlus package combines emnify’s IoT-dedicated cellular access with Skylo’s non-terrestrial network (NTN) satellite service, enabling IoT device manufacturers, OEMs and application and solution providers to add a new level of service enabled by seamless, satellite connectivity failover for devices outside of, or disconnected from, cellular coverage.
SuperNetwork SatPlus opens up a whole new level of IoT connectivity availability for use cases in asset tracking, fleet management, building safety and security, agriculture, and more. IoT businesses can now differentiate their product and service experience and drive their top line revenues by offering a premium level of data connectivity service: ubiquitous coverage even in the most remote areas.
How SuperNetwork SatPlus works
emnify IoT SuperNetwork SatPlus is available in selected European countries and the USA and includes 10MB of cellular connectivity combined with options for 10, 30 or 60 satellite messages per month. With SatPlus, SuperNetwork customers have the security of ubiquitous, uninterrupted IoT connectivity, with seamless switching to satellite networks as devices leave cellular coverage regions. This converged offering is designed for customers that require high availability and a failover solution to be assured that critical application data, such as a high value asset’s position, will always be transmitted.
By enabling both cellular and satellite network access from a single eSIM, single management platform, and single radio module, SatPlus uplevels customer experience and drives down hardware and connectivity costs as it reduces operational overhead associated with adding satellite connectivity.
“Businesses around the world have had to contend with interruptions in their operations and services due to limited terrestrial network infrastructure and rollouts. Bringing together satellite and cellular coverage as a network of networks fills in the blank spaces on the terrestrial coverage map and provides an additional layer of connectivity backup. emnify is excited to be the first to commercially offer this enhanced level of truly global connectivity as part of the expanding emnify IoT SuperNetwork,” said Frank Stoecker, CEO and emnify Co-Founder.
“We are excited to accelerate the availability of the industry’s first converged NTN satellite and cellular connectivity offering through our partnership with emnify,” said Tarun Gupta, CPO and Co-Founder, Skylo. “By delivering satellite and cellular connectivity in a single service, we’re helping IoT businesses increase the reliability and reduce the complexity of IoT connectivity, with a single provider, billing plan, and hardware configuration.”
emnify partners up with leading providers of purpose-built hardware
SatPlus is compatible with market-leading, affordable, converged hardware modules from Murata and IoT chipsets from Sony Semiconductor Israel (Sony), conforming with standard form factors and suitable for a variety of device sizes and designs.
“Designed for cellular IoT applications, the ALT1250 is engineered for devices which prioritize battery life, small size, and global coverage. The 4G/5G LPWA chipset supports 2G, CAT-M, NB-IoT and NB NTN connectivity options and is built to meet the needs of IoT device manufacturers looking to provide new levels of uptime and global coverage across business-critical use cases,” said Dima Feldman, VP Product Management and Marketing at Sony Semiconductor Israel. “Our collaboration with emnify, Murata and Skylo takes our vision forward, enabling IoT devices to connect everywhere.”
Module provider Murata is offering the Type 1SC radio module evaluation board including antenna and application development kit compatible with the SuperNetwork SatPlus service.
“The Type 1SC radio module combined with the Sony ALT1250 chipset and the emnify IoT eSIM provides a compact, low cost, CAT-M & NB-IoT module for a new breed of devices that support both cellular and satellite network protocols to provide global coverage for any type of device,” said Hirokazu Nakae, General Manager, Connectivity Module Product Department at Murata.
Customers interested in getting started with SuperNetwork SatPlus can learn more here. SuperNetwork SatPlus will be generally available in June 2024.
Meet emnify at Mobile World Congress, Barcelona
emnify will be at MWC Barcelona, February 26th to 29th. You can find us at the Berlin Mobile booth in Hall 7 Stand 7B81, or in meeting room 7G70MR. To discuss SuperNetwork SatPlus or any other IoT connectivity requirements, book a meeting: https://www.emnify.com/events/mwc-barcelona
About emnify
emnify is the leading cloud building block for cellular communications in the IoT stack, connecting millions of IoT devices globally – from electric vehicles to energy meters, alarm systems to GPS trackers, thermometers to health wearables. The emnify API and SIM technology connect and secure any kind of IoT deployment to its application back-end. emnify’s cloud-native integrations and no-code workflows ensure seamless lifecycle scalability for deployments of all sizes – from local start-up to global enterprise. The award-winning emnify IoT SuperNetwork is the largest globally distributed mobile cloud core network of its kind, supporting local network access (2G – 5G, LTE-M, NB-IoT and satellite) in over 180 countries from more than 25 cloud regions – and counting. emnify’s solution is built on partnerships with the leading hyperscale cloud service providers, system integrators, and hundreds of network operators worldwide.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220129205/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom